Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients

NCT05158972 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 924

Last updated 2023-11-13

No results posted yet for this study

Summary

Gathering knowledge on the use of Dymista® in Asian patients who receive Dymista® for the first time in routine clinical practice

Conditions

  • Allergic Rhinitis

Interventions

DRUG

Dymista

1 spray per nostril twice daily up to four weeks

Sponsors & Collaborators

  • MEDA Pharma GmbH & Co. KG

    collaborator INDUSTRY
  • Mylan Inc.

    lead INDUSTRY

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-27
Primary Completion
2023-10-24
Completion
2023-10-24

Countries

  • Hong Kong
  • Malaysia
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05158972 on ClinicalTrials.gov